Seaport Therapeutics Q2 2026: Cash Runway Extended to 2029, Pipeline Advances
SPTX sits 38% above its 52-week low of $14.85.
Summary
Seaport Therapeutics posted a wider Q2 net loss of $62.6 million, largely from IPO-related stock compensation, yet holds $427.3 million in cash to fund operations into 2029. Pipeline highlights include positive GlyphAgo Phase 1 data and a new government grant.
Key Events · Earnings and Guidance · SPTX
-
Q2 Net Loss Widens on Stock Comp
Net loss reached $62.6 million in Q2 2026, up from $15.1 million a year ago, primarily due to $34.8 million in non-cash stock-based compensation from IPO-related equity awards.
-
Cash Runway Extended to 2029
Cash, cash equivalents, and investments totaled $427.3 million as of June 30, 2026, which management expects will fund operations into 2029.
-
R&D Spending Surges on Pipeline Progress
R&D expenses rose to $24.6 million in Q2 2026 from $13.4 million in Q2 2025, driven by the Phase 2b BUOY-1 trial for GlyphAllo and the completed Phase 1 trial for GlyphAgo.
-
GlyphAgo Phase 1 Data Positive; Phase 2 Trials Planned
GlyphAgo demonstrated a 6.8-fold increase in bioavailability and favorable safety in Phase 1; the company plans to initiate Phase 2a and 2b trials in H2 2026 and H1 2027.
Analysis · SPTX · Life Sciences
The Q2 2026 10-Q from Seaport Therapeutics shows net loss widening to $62.6 million, fueled by a $34.8 million jump in non-cash stock-based compensation tied to IPO awards. Even so, the balance sheet remains strong with $427.3 million in cash, pushing the runway into 2029. R&D spending nearly doubled year-over-year as the lead depression candidate GlyphAllo progresses through Phase 2b and GlyphAgo reports positive Phase 1 data, with Phase 2 trials on deck. A new $15.2 million ARPA-H grant adds non-dilutive support. While the compensation spike clouds operating expense trends, the real story for investors is the underlying cash burn and pipeline momentum.
At the time of this filing, SPTX was trading at $20.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $14.85 to $22.98. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.